News

Sellas Life Sciences Stock Triples After Cancer Vaccine Data

Bloomberg

Sellas Life Sciences Group Inc. surged after the drug developer reported positive late-stage trial results for an experimental cancer vaccine to treat an aggressive form of blood cancer.

Read the full Veytics brief

We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.